Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System.

Yeramaneni, Samrat; Doshi, Pratik; Sands, Kenneth; Cooper, Mandelin; Kurbegov, Dax; Fromell, Gregg

Yeramaneni, Samrat; Doshi, Pratik; Sands, Kenneth; Cooper, Mandelin; Kurbegov, Dax; Fromell, Gregg.

Yeramaneni S; Sarah Cannon Research Institute, HCA Healthcare, Nashville, Tennessee.
Doshi P; Sarah Cannon Research Institute, HCA Healthcare, Nashville, Tennessee.
Sands K; Clinical Operations Group, HCA Healthcare, Nashville, Tennessee.
Cooper M; Clinical Operations Group, HCA Healthcare, Nashville, Tennessee.
Kurbegov D; Sarah Cannon Research Institute, HCA Healthcare, Nashville, Tennessee.
Fromell G; HCA Research Institute, HCA Healthcare, Nashville, Tennessee. Electronic address: Gregg.Fromell@HCAHealthcare.com.

Gastroenterology ; 160(3): 919-921.e3, 2021 02.

Article in English | MEDLINE | ID: covidwho-1575967

Subject(s)

Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Famotidine/therapeutic use; Hospitalization; COVID-19/diagnosis; COVID-19/mortality; Hospital Mortality; Humans; Intubation, Intratracheal; Retrospective Studies; Risk Assessment; Risk Factors; Tennessee; Time Factors; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Famotidine / COVID-19 Drug Treatment / Hospitalization Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Gastroenterology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google